---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-425684"
form_type: "8-K"
ticker: "ODTX"
cik: "0001882782"
company_name: "Odyssey Therapeutics, Inc."
filed_at: "2026-10-20T11:00:21+00:00"
generated_at: "2026-10-20T11:05:20.587906+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Odyssey OD-001 Phase 2a UC induction: 27% clinical remission at 20mg BID; primary endpoint met

## Summary
- Primary endpoint met: mean 2.4-point reduction in modified Mayo score at Week 12 across 56 efficacy-evaluable patients (p<0.001).
- 20 mg BID (n=41): clinical remission 27%, clinical response 61%, symptomatic remission 49%; 10 mg BID (n=15): 20%, 40%, 27%.
- At 20 mg BID, hsCRP and circulating neutrophils fell significantly and serum albumin rose; remission was 16% in MES 3 patients (n=19) and 29%/23% in therapy-naive/experienced.
- No serious adverse events, serious infections, treatment-related discontinuations or liver-function abnormalities; 3 drug-related AEs at 20 mg BID (2 fevers, 1 headache).
- Plans randomized placebo-controlled Phase 2b monotherapy and Phase 2a OD-001 plus vedolizumab combo; topline induction data expected H2 2027.

## SEC filing metadata
- accession: 0001193125-26-425684
- form_type: 8-K
- ticker: ODTX
- cik: 0001882782
- company_name: Odyssey Therapeutics, Inc.
- filed_at: 2026-10-20T11:00:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/0001193125-26-425684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/odtx-20261020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-425684
- JSON: https://secwatch.observer/filing/0001193125-26-425684.json
- Plain text: https://secwatch.observer/filing/0001193125-26-425684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.